Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development and Validation of a Post-operative Risk Of Local Recurrence Model Integrating Serology and Evalution (PROMISE) in Local Advanced Rectal Cancer Receiving Neoadjuvant Therapy: a Multicenter Study

NCT07351708 is registered in ClinicalTrials.gov with Cai Zerong as lead sponsor.

NCT NCT07351708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07351708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development and Validation of a Post-operative Risk Of Local Recurrence Model Integrating Serology and Evalution (PROMISE) in Local Advanced Rectal Cancer Receiving Neoadjuvant Therapy: a Multicenter Study
Lead sponsor
Cai Zerong
Phase
Observational
Overall status
Completed
Start date
January 6, 2010
Completion date
November 30, 2025
Enrollment
2,315 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal cancer (larc)